In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New hospital purchasing guidelines in Germany could force medtech companies to rethink traditional strategies

This article was originally published in Clinica

Executive Summary

The German market for medical devices is by no means as open to innovation as it was a few years ago. The criteria for paying for treatment by health insurers have been expanded to include cost-efficiency although the evaluation formulae have not yet been established. But, say consultants Hans-Jurgen Wildau and Bernd Grohs, potentially expensive outlays for developing innovative medical products can be reduced by integrating partners from different healthcare sectors early on.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT081660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel